This is to inform that due to some circumstances beyond the organizer control, "2nd Edition of International Summit on Hematology and Blood Disorders" (Hematology 2026) October 08 -10, 2026 | Tokyo, Japan has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at hematology@magnusconference.com or call + 1 (702) 988 2320.
Myeloproliferative neoplasms are chronic clonal disorders characterized by overproduction of mature blood cells. These conditions may lead to thrombosis, bleeding, and progression to bone marrow fibrosis or acute leukemia. Diagnosis relies on clinical features, laboratory findings, bone marrow evaluation, and molecular testing. Management focuses on symptom control, prevention of complications, and modification of disease course. Advances in targeted therapies have significantly improved patient outcomes. Ongoing research aims to better understand disease biology, optimize treatment strategies, and improve long-term prognosis. Myeloproliferative neoplasms remain an important area of investigation within hematologic malignancies.
Title : Acute intermittent porphyria: A neurological dilemma obscured by ubiquitous gastrointestinal presentation
Mayank Anand Singh, Mimer Medical College, India
Title : Comprehensive symptom management and supportive nursing care in a preterm toddler undergoing HSCT for pyruvate kinase deficiency
Tran Thi Dung, Vinmec International Hospital, Vietnam
Title : Enhancing Thalassemia Gene Carrier Identification in Non-anemic Populations Using AI Erythrocyte Morphology Analysis and Machine Learning
Junxun Li, First Affiliated Hospital, Sun Yat-sen University, China
Title : Predictive Value of Routine Laboratory Tests for Early Death in Pediatric Hemophagocytic Lymphohistiocytosis Patients
Junxun Li, First Affiliated Hospital, Sun Yat-sen University, China
Title : Eltrombopag added to combined immunosuppressive therapy IST in children with acquired severe aplastic anemia accelerates hematologic recovery and should be continued in the second course of IST
Olga Goronkova, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology , Russian Federation
Title : Arsenic Trioxide and Its Applications
Peng Zhang, Chief physician, China